{"entity":{"id":"nct07126665","kind":"trial","name":"A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of QLC5508 in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.","summary":"A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT07126665 by Minghui Pharmaceutical (Hangzhou) Ltd, with 116 participants planned, started 2025-09-18 and due to reach its primary completion in 2029-08. Interventions recorded: MHB088C for Injection and MHB039A for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07126665","url":"https://clinicaltrials.gov/study/NCT07126665"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["qlc5508"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07126665","phase":"1/2","setting":"An Open-label Phase I/II Clinical Study of MHB088C for Injection Combined With MHB039A for Injection in Patients With Advanced Malignant Solid Tumors","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","enrolled":116,"outcomes":[]},"route":"/trials/nct07126665/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"mhb039a","kind":"drug","name":"MHB039A","route":"/drugs/mhb039a/"},{"id":"qlc5508","kind":"drug","name":"QLC5508","route":"/drugs/qlc5508/"}]}}